Taysha Gene Therapies, Inc. TSHA Current maturities of long-term debt
Current maturities of long-term debt at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityCurrent.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s current maturities of long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s current maturities of long-term debt?
- Taysha Gene Therapies, Inc. (TSHA) reported current maturities of long-term debt of $275K in Q1 2026.
- How has Taysha Gene Therapies, Inc.'s current maturities of long-term debt changed year-over-year?
- Taysha Gene Therapies, Inc.'s current maturities of long-term debt decreased by 31.6% year-over-year, from $402K to $275K.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s current maturities of long-term debt?
- Over 3 years (2022 to 2025), Taysha Gene Therapies, Inc.'s current maturities of long-term debt has grown at a 5.8% compound annual growth rate (CAGR), from $320K to $379K.